Merck builds in cell, gene therapies with Mirus Bio deal
pharmaphorum
MAY 23, 2024
Merck KGaA has agreed to a $600m deal to buy Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies.
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
pharmaphorum
MAY 23, 2024
Merck KGaA has agreed to a $600m deal to buy Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies.
Pharmaceutical Technology
APRIL 3, 2023
The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Polyplus, based in Strasbourg, France, produces key components in the production of viral vectors used in cell and gene therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
MAY 23, 2024
The German drugmaker is bolstering its MilliporeSigma business with a unit of Gamma Biosciences that specializes in so-called transfection reagents.
BioPharma Reporter
AUGUST 14, 2023
Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.
Drug Discovery World
FEBRUARY 21, 2024
We are delighted to be further backing MIP as they are making significant technical progress.” The post £7M financing to drive commercialisation in cell and gene therapy appeared first on Drug Discovery World (DDW).
Camargo
MAY 2, 2021
Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well as a new motivation for regulators to provide clear, efficient pathways for product developers. Background: The Advancement of Cell and Gene Therapies.
BioPharma Reporter
FEBRUARY 22, 2024
MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a Â7 million Series A financing round, led by Mercia Ventures.
Advarra
NOVEMBER 29, 2022
The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.
BioPharma Reporter
AUGUST 18, 2021
Recombinant adeno-associated viruses (rAAVs) are becoming the vector of choice for delivering gene therapies, says the French firm.
Drug Discovery World
MAY 16, 2023
What are the global innovations in cell and gene therapy? What opportunities and challenges are emerging and can therapies get to market faster? They note that the gene therapy market in general, and the lentiviruses market by association, is growing enormously. DDW’s Megan Thomas finds out.
BioPharma Reporter
JULY 5, 2021
Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.
BioPharma Reporter
JUNE 29, 2021
The New York based company said the deal will expand its in vitro diagnostic, cell and gene therapy support capabilities.
Roots Analysis
APRIL 5, 2023
In fact, non-viral vectors are significantly less expensive than their virus-based counterparts, implying the potential for use in the development of more affordable gene therapies. Currently, highest number of patent for non-viral transfection reagents and systems is filed in North America region.
Drug Discovery World
AUGUST 11, 2023
The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients. News round-up for by DDW Digital Content Editor Diana Spencer.
Drug Discovery World
SEPTEMBER 25, 2023
CRISPR gene editing companies Integrated DNA Technologies (IDT) and Aldevron have inked a new global distribution agreement to expand CRISPR products for cell and gene therapy customers.
BioTech 365
SEPTEMBER 2, 2020
Ready-to-use kit enables rapid adeno-associated virus (AAV) titer determinations during the manufacture of AAV vectors UPPSALA, Sweden–(BUSINESS WIRE)–Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and a leading provider of peptide synthesizers and reagents, today announced the introduction … Continue (..)
Roots Analysis
JUNE 1, 2022
Recent technological advancements have led to development of novel DNA cloning kits and reagents, which are cost-effective, faster and more efficient than conventional methods. DNA Cloning Reagent Providers – Current Market Landscape. DNA Cloning Reagents Market. DNA Cloning Kit Providers – Current Market Landscape.
FDA Law Blog
JANUARY 4, 2023
The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023. The Agency referred to its 2011 FDA Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products during the town hall. Common CMC Issues for Phase 1 IND Study.
Drug Discovery World
JANUARY 30, 2024
Viral vector manufacturing At the Advanced Therapies Awards ceremony, Dr Luigi Naldini, Director of the San Raffaele Telethon Institute for Gene Therapy, was awarded a Lifetime Achievement Award in recognition of ‘extraordinary contributions to gene therapy’, a field he has helped shape through his pioneering work on lentiviral vectors.
Drug Discovery World
MARCH 27, 2023
Download this new white paper ‘Diving deep into cell therapy: An industry perspective’ to find out more. The post New whitepaper: Take a deep dive into cell therapy appeared first on Drug Discovery World (DDW).
Drug Discovery World
MARCH 27, 2023
Cell therapy research has never been more exciting with all of the research ongoing.
The Pharma Data
MAY 17, 2021
Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Posted 17 May 2021 | By Joanne S. Eglovitch . Historical origins. .
Drug Discovery World
APRIL 3, 2023
As the industry’s awareness of alternatives to traditional antibodies continues to grow, there is increasing demand for these alternatives, which we are seeing particularly within the therapeutic sector, to enable targeted therapeutics and enable the emerging gene therapy market. DS: The company now has clients across big pharma.
Roots Analysis
FEBRUARY 21, 2022
Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production. As a result, NGS library preparation kits have emerged as an innovative technology to overcome the challenges associated with conventional library preparation protocols.
pharmaphorum
DECEMBER 16, 2022
Maishman brings a wealth of experience to the cell and gene therapy-focused company, having worked at GlaxoSmithKline, Pfizer, Valneva, Alexion, and Recipharm in various leadership roles. Pete previously worked with Amazon, Babylon Health, and Sony. Other pharma supplier hires.
Drug Discovery World
MARCH 13, 2023
The cell and gene therapy (CGT) landscape has grown significantly in the past year. Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. link] “COVID-19 and cell and gene therapy: How to keep innovation on track.”
Roots Analysis
FEBRUARY 23, 2022
In the past two years, close to 3,220 patents related to NGS library preparation kits and reagents have been filed / granted, indicating the heightened pace of innovation. Next Generation Sequencing (NGS) Library Preparation Kits. Strong Intellectual Property Portfolio. Next Generation Sequencing (NGS) Library Preparation Kits.
Pharmaceutical Technology
FEBRUARY 3, 2023
With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.
The Pharma Data
OCTOBER 14, 2020
Bio-Techne’s Woburn facility produces Cloudz Cell Activation Kits, a magnetic-free bead-based technology for the robust and reliable expansion of immune cells, including T cells and NK cells, representing a pivotal component of the cell and gene therapy workflow. ” About Bio-Techne Corporation (NASDAQ: TECH).
Drug Discovery World
DECEMBER 23, 2022
GenScript USA has expanded its global current Good Manufacturing Practices (cGMP) single-guide RNA (sgRNA) manufacturing capabilities to meet the growing demand for cell and gene therapies. . The 400,000 square-foot cGMP facility enables gene and cell therapy R&D programmes to advance IND filings and clinical trials.
Drug Discovery World
SEPTEMBER 28, 2022
To further streamline the customer experience, optimised reagent kits with validated antibodies from PerkinElmer’s BioLegend business are also part of the solution. . The post Cell analysis system could streamline cell and gene therapy manufacturing appeared first on Drug Discovery World (DDW). ” . .
Drug Discovery World
MAY 7, 2024
The goal of these approaches is to improve process economics by eliminating steps and the amount of reagents, water and buffer. There have been numerous studies that have documented the ability to reduce time and labor, along with reagents and consumables, with single-use technologies compared to its counterpart.
Drug Discovery World
OCTOBER 13, 2022
There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. .
Drug Discovery World
JANUARY 19, 2023
This paid-for advertorial by Catalent appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 One significant challenge in the manufacturing of cell and gene therapies is the production of high-quality plasmid DNA (pDNA). Figure 1: The integrated development pathway for cell and gene therapies.
Drug Discovery World
FEBRUARY 8, 2023
Svea Cheeseman , Refeyn, explains why better efficiency is needed to advance the production of viral vectors for use in gene therapies. Adeno-associated viruses (AAVs) are a promising, widely used vector for delivering gene therapies. Data were provided by the Cell and Gene Therapy Catapult (London, UK).
Drug Discovery World
OCTOBER 12, 2022
Furthermore, the sensitivity of the fluorescent label was shown to be around x100 greater than 2-aminobenzamide, a reagent that has been used extensively in the past to label glycans. . Agilent’s next round of collaboration will look at cell and gene therapy glycan applications. The glycan database . References .
Drug Discovery World
JUNE 14, 2023
In addition to the collection, processing and storing of adult blood projects, BCA is also involved in providing umbilical cord blood and other tissue products as critical components of cell therapies. One example we are following with anticipation are the two FDA approvals for the first gene therapies for sickle cell disease.
Drug Discovery World
DECEMBER 15, 2022
Improve delivery: Clinical translation of gene therapy is dependent on the efficient and safe delivery of gene editing tools into cells, and this can occur either ex vivo or in vivo. In one example, Choi et al.
Drug Discovery World
JULY 18, 2023
Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases.
Drug Discovery World
FEBRUARY 27, 2023
By focusing on workflow simplification and expanded assay capabilities in a state-of-the-art microplate reader, complemented by our optimised reagent technologies, our team has created an all-around high-performing system built for today and the future.”
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content